Clinical trial
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic…
NCT02453256 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT02453256 |
|---|---|
| Title | A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) |
| Official title | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis |
| Acronym | focuSSced |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Systemic Sclerosis |
| Intervention type | Drug |
| Interventions | Placebo, Tocilizumab |
| Enrollment | 212 |
| Start date | Nov 20, 2015 |
| Primary completion | Jan 15, 2018 |
| Completion | Feb 4, 2019 |
| First posted | May 25, 2015 |
| Last update posted | Mar 9, 2020 |
| Countries | Argentina, Belgium, Bulgaria, Canada, Denmark, France, Germany, Greece, Hungary, Italy, Japan, Lithuania and 10 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: